Franz Gruber

2.5k total citations
20 papers, 743 citations indexed

About

Franz Gruber is a scholar working on Hematology, Genetics and Rheumatology. According to data from OpenAlex, Franz Gruber has authored 20 papers receiving a total of 743 indexed citations (citations by other indexed papers that have themselves been cited), including 17 papers in Hematology, 13 papers in Genetics and 11 papers in Rheumatology. Recurrent topics in Franz Gruber's work include Chronic Myeloid Leukemia Treatments (15 papers), Chronic Lymphocytic Leukemia Research (13 papers) and Eosinophilic Disorders and Syndromes (11 papers). Franz Gruber is often cited by papers focused on Chronic Myeloid Leukemia Treatments (15 papers), Chronic Lymphocytic Leukemia Research (13 papers) and Eosinophilic Disorders and Syndromes (11 papers). Franz Gruber collaborates with scholars based in Norway, Finland and Germany. Franz Gruber's co-authors include Kimmo Porkka, Andreas Hochhaus, Thoralf Lange, Thomas Ernst, Martin C. Müller, Michele Baccarani, Giuseppe Saglio, Nicholas C.P. Cross, Giovanni Martinelli and Fabrizio Pane and has published in prestigious journals such as Blood, PLoS ONE and Arteriosclerosis Thrombosis and Vascular Biology.

In The Last Decade

Franz Gruber

20 papers receiving 722 citations

Peers

Countries citing papers authored by Franz Gruber

Since Specialization

Citations

This map shows the geographic impact of Franz Gruber's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Franz Gruber with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Franz Gruber more than expected).

Fields of papers citing papers by Franz Gruber

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Franz Gruber. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Franz Gruber. The network helps show where Franz Gruber may publish in the future.

Co-authorship network of co-authors of Franz Gruber

This figure shows the co-authorship network connecting the top 25 collaborators of Franz Gruber. A scholar is included among the top collaborators of Franz Gruber based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Franz Gruber. Franz Gruber is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Dynamical models of mutated chronic myelogenous leukemia cells for a post-imatinib treatment scenario: Response to dasatinib or nilotinib therapy 2017 ·PLoS ONE ·Clemens Woywod, Franz Gruber, Richard A. Engh, Tor Flå	4
2	Data driven polypharmacological drug design for lung cancer: analyses for targeting ALK, MET, and EGFR 2017 ·Journal of Cheminformatics ·(unknown), Osman Gani, Franz Gruber, Richard A. Engh	3
3	Safety and efficacy of the combination of pegylated interferon-α2b and dasatinib in newly diagnosed chronic-phase chronic myeloid leukemia patients 2016 ·Leukemia ·Henrik Hjorth‐Hansen, Jesper Stentoft, Johan Richter, Perttu Koskenvesa, Martin Höglund, Arta Dreimane, Kimmo Porkka, Tobias Gedde‐Dahl, Bjørn Tore Gjertsen, Franz Gruber, Leif Stenke, (unknown), Berit Markevärn, Anna Lübking, Hanne Vestergaard, Lene Udby, Ole Weis Bjerrum, Inger Persson, Satu Mustjoki, Ulla Olsson‐Strömberg, (unknown)	49
4	Safety and Efficacy of Addition of Pegylated Interferon alpha2b to Standard Dose Dasatinib in Newly Diagnosed Chronic Phase CML Patients 2015 ·Blood ·Henrik Hjorth‐Hansen, Jesper Stentoft, Johan Richter, Perttu Koskenvesa, Arta Dreimane, Kimmo Porkka, Tobias Gedde‐Dahl, Bjørn Tore Gjertsen, Franz Gruber, Martin Höglund, Anna Lübking, Kristina Myhr‐Eriksson, Berit Markevärn, Hanne Vestergaard, Ole Weis Bjerrum, Leif Stenke, Satu Mustjoki, Ulla Strömberg	8
5	The quantitative level of T315I mutated BCR-ABL predicts for major molecular response to second-line nilotinib or dasatinib treatment in patients with chronic myeloid leukemia 2012 ·Haematologica ·Thoralf Lange, Thomas Ernst, Franz Gruber, Jacqueline Maier, Michael Cross, Marcus Müller, Dietger Niederwieser, Andreas Hochhaus, Markus Pfirrmann	17
6	Circulating monocytes mirror the imbalance in TF and TFPI expression in carotid atherosclerotic plaques with lipid-rich and calcified morphology 2011 ·Thrombosis Research ·(unknown), Mikhail A. Sovershaev, Elena M. Egorina, Franz Gruber, Vladimir Y. Bogdanov, John T. Fallon, Bjarne Østerud, Ellisiv B. Mathiesen, John‐Bjarne Hansen	10
7	BCR-ABL kinase domain mutation analysis in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors: recommendations from an expert panel on behalf of European LeukemiaNet 2011 ·Blood ·Simona Soverini, Andreas Hochhaus, Franck E. Nicolini, Franz Gruber, Thoralf Lange, Giuseppe Saglio, Fabrizio Pane, Martin C. Müller, Thomas Ernst, Gianantonio Rosti, Kimmo Porkka, Michele Baccarani, Nicholas C.P. Cross, Giovanni Martinelli	370
8	BCR-ABL isoforms associated with intrinsic or acquired resistance to imatinib: more heterogeneous than just ABL kinase domain point mutations? 2011 ·Medical Oncology ·Franz Gruber, Tuija Lundán, Rasmus Goll, (unknown), Ingvild Mikkola, Ole Petter Rekvig, Sakari Knuutila, Kari Remes, Tobias Gedde‐Dahl, Kimmo Porkka, Henrik Hjorth‐Hansen	11
9	Absolute Quantification of Mutant T315I BCR-ABL Transcripts At 6 Months Identifies Imatinib Resistant CML Patients with a Low Probability to Achieve MMR After 12 Months on Second Line Tyrosine Kinase Therapy 2011 ·Blood ·Thoralf Lange, Thomas Ernst, Markus Pfirrmann, Jacqueline Maier, Martin C. Müller, Franz Gruber, Dietger Niederwieser, Andreas Hochhaus	1
10	The role of TFPI in regulation of TF-induced thrombogenicity on the surface of human monocytes 2010 ·Thrombosis Research ·(unknown), Franz Gruber, Mikhail A. Sovershaev, (unknown), Bjarne Østerud, Lars C. Petersen, John‐Bjarne Hansen	18
11	A co-operative evaluation of different methods of detecting BCR-ABL kinase domain mutations in patients with chronic myeloid leukemia on second-line dasatinib or nilotinib therapy after failure of imatinib 2009 ·Haematologica ·Thomas Ernst, Franz Gruber, (unknown), Jacqueline Maier, Markus Pfirrmann, Marcus Müller, Ingvild Mikkola, Kimmo Porkka, D. Niederwieser, Andreas Hochhaus, Thoralf Lange	27
12	Impact of tyrosine kinase inhibitors on patient outcomes in Philadelphia chromosome‐positive acute lymphoblastic leukaemia 2009 ·British Journal of Haematology ·Franz Gruber, Satu Mustjoki, Kimmo Porkka	41
13	Chronic Myelogenous Leukemia with the e6a2 <i>BCR-ABL</i> and Lacking Imatinib Response: Presentation of Two Cases 2009 ·Acta Haematologica ·(unknown), Franz Gruber, (unknown), Randi Hovland, Henrik Hjorth‐Hansen, Tobias Gedde‐Dahl, Peter Meyer	9
14	Detection of Drug-Resistant Clones in Chronic Myelogenous Leukemia Patients during Dasatinib and Nilotinib Treatment 2009 ·Clinical Chemistry ·Franz Gruber, Thomas Ernst, Yury Kiselev, Andreas Hochhaus, Ingvild Mikkola	10
15	High tissue factor‐expressing human monocytes carry low surface CD36: application to intersubject variability 2007 ·Journal of Thrombosis and Haemostasis ·Mikhail A. Sovershaev, Elena M. Egorina, Franz Gruber, Jan Ole Olsen, Bjarne Østerud	7
16	Extracellular Signal-Regulated Protein Kinase 5 Mediates Resistance of Human Chronic Myeloid Leukemia K562 Cells to Imatinib. 2006 ·Blood ·Mikhail A. Sovershaev, Elena M. Egorina, Franz Gruber, Geir Bjørkøy, Terje Johansen	1
17	Selecting and deselecting imatinib-resistant clones: observations made by longitudinal, quantitative monitoring of mutated BCR-ABL 2005 ·Leukemia ·Franz Gruber, Trond Lamark, (unknown), Mikhail A. Sovershaev, (unknown), Tobias Gedde‐Dahl, (unknown), Bjøŕn Skogen	40
18	Intracellular and Surface Distribution of Monocyte Tissue Factor 2005 ·Arteriosclerosis Thrombosis and Vascular Biology ·Elena M. Egorina, Mikhail A. Sovershaev, Geir Bjørkøy, Franz Gruber, Jan Ole Olsen, Behnaz Parhami-Seren, Kenneth G. Mann, Bjarne Østerud	115
19	Quantitative Analyses of BCR-ABL Mutations Associated with Imatinib Treatment in CML. 2005 ·Blood ·Franz Gruber, (unknown), (unknown), (unknown), Bjøŕn Skogen, Tobias Gedde‐Dahl, Tuija Lundán, Kimmo Porkka, Bengt Simonsson, Berit Markevärn, Hans Wadenvik, Leif Stenke	1
20	High Sensitive Detection of Imatinib-Resistance Associated Mutations Based on ARMS-PCR. 2004 ·Blood ·Franz Gruber, (unknown), (unknown), (unknown)	1

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact